Name of the issue: Emcure Pharmaceuticals Limited

1	**Type of issue (IPO/ FPO)**	IPO
2	**Issue size (Rs. in crore)**	1,952.00
3	**Grade of issue alongwith name of the rating agency**	
	Name	Not Applicable
	Grade	
4	**Subscription Level (Number of times)** [1]	48.14

Source: Minutes for Basis of Allotment dated July 8, 2024

(1) Figure is after technical rejections

5 **QIB holding (as a %age of total outstanding capital) as disclosed to stock exchanges**

Particulars	%
(i) On Allotment July 8, 2024	5.10%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (September 30, 2024)	6.87%
(iii) at the end of 1st FY (March 31, 2025)	6.51%
(iv) at the end of 2nd FY (March 31, 2026)	9.45%
(v) at the end of 3rd FY (March 31, 2027)*	N.A.

**will be updated in due course*

6 **Financials of the issuer (consolidated basis)** *(Rs. Million)*

Parameters	31-Mar-25	31-Mar-26	31-Mar-27
Revenue from operations	78959.97	92035.4	Not Available
Net Profit for the period	7074.67	9412.69	Not Available
Paid up equity share capital	1894.83	1895.9	Not Available
Other Equity	42567.03	47604.42	Not Available

Note: Financials for the year ended March 31, 2027 shall be updated in due course

7 **Trading status in the scrip of the issuer**

Company's Equity Shares are listed on both BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE")

Particulars	Status
(i) at the end of 1st FY (March 31, 2025)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2026)	Frequently Traded
(iii) at the end of 3rd FY (March 31, 2027) [1]	Not Available

(1) will be updated in due course

All the above information is updated till November 15 , 2026 unless indicated otherwise

8 **Change, if any, in directors of issuer from the disclosures in the offer document**

Particulars	Name of Director	Appointed / Resigned
During year ended March 31, 2025	Samonnoi Banerjee	Resigned
During year ended March 31, 2026	Mukund Gurjar	Re-appointment
	Dr. Shailesh Kripalu Ayyangar	Re-appointment
	Vijay Keshav Gokhale	Re-appointment
	C S Muralidharan	Appointment
	Dr. Vidya Rajiv Yeravdekar	Re-appointment
During year ended March 31, 2027 [(1)]	Satish Mehta	Re-appointment
	Berjis Desai	Retirement
	Raghu Kumar	Appointment
	Namita Thapar	Re-appointment
	P.S. Jayakumar	Cessation

(1) Change in Directors of Issuer is not updated as the relevant financial years have not been completed

9 **Status of implementation of project/ commencement of commercial production**

Particulars	Remarks
(i) as disclosed in the offer document	Not Applicable
(ii) Actual implementation	Not Applicable
(iii) Reasons for delay in implementation, if any	Not Applicable

10 **Status of utilization of issue proceeds**

(i) as disclosed in the offer document

Rs. in Million

Particulars	Amount which will be financed from Net Proceeds	Estimated Utilisation of Net Proceeds	
		FY 2025	FY 2026
Repayment/ prepayment, in full or in part of certain outstanding borrowings availed by the Company	6,000	6,000	0
General corporate purposes	1588.64	1191.48	397.16
Total	**7588.64**	**7191.48**	**397.16**

(ii) Actual utilization	Fully utilised
(iii) Reasons for deviation, if any	None

11 **Comments of monitoring agency, if applicable**

(i) Comments on use of funds	None
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	None
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	None

12 **Price-related data**

Designated SE	NSE
Issue Price (Rs.)	1008
Listing Date	July 10, 2024

Price parameters	At close of listing day-July 10, 2024	At close of 30th calendar day from listing day	At close of 90th calendar day from listing day	As at the end of March 31, 2025		
				Closing price during FY	High during FY	Low during FY
Market Price	1359.15	1,289.65	1,331.35	1,072.40	1,580.00	910.95
Nifty 50	24,324.45	24,117.00	24,795.75	23,519.35	26,277.35	21,281.45

Price parameters	As at the end of March 31, 2026			As at the end of March 31, 2027		
	Closing price during FY	High during FY	Low during FY	Closing price during FY	High during FY	Low during FY
Market Price	1,595.50	1,671.80	889.00	Not Available	Not Available	Not Available
Nifty 50	22,331.40	26,373.20	21,743.65	Not Available	Not Available	Not Available

Source: Stock Exchange data. Where the 90th day/ March 31 of a particular year falls on a holiday, the immediately preceeding trading day has been considered

13 **Basis for Issue Price and Comparison with Peer Group & Industry Average**

Accounting ratio	Name of company	Face Value (Rs.)	As disclosed in the offer document	At the end of 1st FY March 31, 2025	At the end of 2nd FY March 31, 2026	At the end of 3rd FY March 31, 2027**
EPS	**Issuer: Consolidated** [1]	10	27.54	36.43	48.77	-
	Peer Group:					
	Dr. Reddy's Laboratories Limited	5	334.59	67.78	51.42	
	Cipla Limited	2	51.01	65.24	48	
	Alkem Laboratories Limited	2	150.19	181.11	192.51	
	Torrent Pharmaceuticals Limited	5	48.94	56.47	63.92	
	Mankind Pharma Limited	1	47.68	49.2	46.28	
	Abbott India Limited	10	565.28	665.62	730.36	
	J. B. Chemicals & Pharmaceutica	1	34.85	41.56	44.45	
	Industry Avg		176.08	161.00	168.13	
P/E	**Issuer: Consolidated**	10	36.6	29.45	32.71	-
	Peer Group:					
	Dr. Reddy's Laboratories Limited	5	17.93	16.88	24.40	
	Cipla Limited	2	30.1	22.10	25.50	
	Alkem Laboratories Limited	2	33.86	26.94	27.53	
	Torrent Pharmaceuticals Limited	5	57.74	57.28	66.02	
	Mankind Pharma Limited	1	45.3	49.25	43.34	
	Abbott India Limited	10	47.43	46.17	35.48	
	J. B. Chemicals & Pharmaceutica	1	50.49	39.03	46.44	
	Industry Avg		40.41	36.81	38.39	

All the above information is updated till November 15 , 2026 unless indicated otherwise

RoNW%	**Issuer: Consolidated [3]**	10	16.87%	15.32%	18.67%	-
	Peer Group:					
	Dr. Reddy's Laboratories Limited	5	19.74%	16.96%	11.36%	
	Cipla Limited	2	15.43%	16.90%	11.27%	
	Alkem Laboratories Limited	2	17.41%	18.07%	16.66%	
	Torrent Pharmaceuticals Limited	5	24.15%	25.17%	25.78%	
	Mankind Pharma Limited	1	20.43%	13.89%	11.74%	
	Abbott India Limited	10	32.48%	33.41%	32.51%	
	J. B. Chemicals & Pharmaceutica	1	18.90%	19.21%	17.06%	
	Industry Avg:		21.22%	20.52%	18.05%	
NAV per share	**Issuer: Consolidated [4]**	10	163.22	234.65	261.09	-
	Peer Group:					
	Dr. Reddy's Laboratories Limited	5	1693.75	399.53	451.76	
	Cipla Limited	2	330.78	386.24	426.25	
	Alkem Laboratories Limited	2	862.46	1002.37	1155.87	
	Torrent Pharmaceuticals Limited	5	202.57	224.29	247.87	
	Mankind Pharma Limited	1	233.73	347.39	394.85	
	Abbott India Limited	10	1740.17	1992.14	2246.75	
	J. B. Chemicals & Pharmaceutica	1	188.37	220.54	259.05	
	Industry Avg:		750.26	653.21	740.34	

(1) Diluted earnings per share (in Rs.) = Diluted EPS refers to the diluted earnings per share of the respective company

(2)P/E: P / E Ratio has been computed based on the closing market price of equity shares on BSE on June 21, 2024, divided by the Diluted EPS for the year ended March 31, 2024

(3) RoNW is computed as profit attributable to owners of the company divided by Total Equity attributable to the owners

(4) Net Asset Value per Equity Share is is computed as the closing net worth divided by the equity shares outstanding as on March 31, 2024

***Not available as the relevant fiscal year has not been completed / information not disclosed*

14 **Any other material information**

Particulars	Date
Emcure Pharmaceuticals Limited ("Emcure"), together with its subsidiary, Gennova Biopharmaceuticals Limited ("Gennova"), has entered into a Share Subscription and Shareholders' Agreement dated July 25, 2024 to acquire 26% of Sunsure Solarpark Twelve Private Limited	July 25, 2024
Emcure Pharmaceuticals Limited ("Emcure"), has entered into a Share Subscription and Shareholders' Agreement and Power Transfer Agreement(s) dated June 02, 2025 with Torrent Urja 37 Private Limited	June 02, 2025
The Board of Directors of the Company has approved the acquisition of 4,095,180 Equity Shares, constituting 20.42% of the total issued and paid up capital of Zuventus Healthcare Limited ("Zuventus"), a subsidiary of the Company, from all its individual shareholders, thereby making Zuventus a wholly-owned subsidiary of the Company.	June 21, 2025
No-objection Letter from NSE vide their letter no: NSE/LIST/COMP/EMCURE/493/2025-2026 dated November 17, 2025 and BSE vide their letter no: LIST/COMP/DN/555/2025-26 dated November 17, 2025 for the reclassification of certain persons from "Promoter and Promoter Group" category to "Public" category, in accordance with Regulation 31A of the SEBI Listing Regulations.	November 18, 2025
Search and seizure/ inspection operation conducted by the Goods & Service Tax Department, Mumbai, Maharashtra, at the Offices of the Company. The operation commenced on November 24, 2025 at 12.15 p.m. and concluded on November 26, 2025 at 5.00 p.m.	November 27, 2025
There was an incident of fire at the utility block of our manufacturing plant (Plant I) located at Hinjawadi, Pune, Maharashtra. The reason of the fire is yet to be ascertained. The fire was controlled but the operation of the said manufacturing plant is temporarily disrupted for an estimated period of 5 to 7 days. There are no human injuries or casualties reported.	February 07, 2026
Marcan Pharmaceuticals Inc., a subsidiary of the Company ("Marcan") has on July 02, 2026 (EDT) entered into share purchase agreements with certain shareholders of Mantra Pharma Inc., a step-down subsidiary of the Company ("Mantra"), to acquire all of Class E Special Shares in the share capital of Mantra. Consequently, Mantra continues to be 100% subsidiary of Marcan	July 3, 2026

Gennova Biopharmaceuticals Limited, a Subsidiary of the Company, has executed a Business Transfer Agreement for transfer of its mRNA business as a going concern on a slump sale basis to Immunoscript Life Science Private Limited on July 10, 2026	July 11, 2026
Company has executed Share Transfer Agreements with all the individual shareholders of Gennova Biopharmaceuticals Limited (“Gennova”), a subsidiary of the Company, for acquisition of 663,865 Equity Shares, constituting 12.05% of the total issued and paid up capital of Gennova. Upon completion of the aforesaid acquisition, Gennova would become a wholly-owned subsidiary of the Company	July 13, 2026
Company has approved the draft Composite Scheme of Amalgamation amongst Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited (collectively referred to as the “Transferor Companies") both being wholly owned subsidiaries of the Company with Emcure Pharmaceuticals Limited (hereinafter referred to as the “Company” or “Transferee Company”) and their respective shareholders and creditors pursuant to Sections 230 to 232 and other applicable provisions of the Companies Act, 2013	October 12, 2026
For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com	

All the above information is updated till November 15 , 2026 unless indicated otherwise